1. MicroRNA-219 loaded chitosan nanoparticles for treatment of glioblastoma.
- Author
-
Alswailem R, Alqahtani FY, Aleanizy FS, Alrfaei BM, Badran M, Alqahtani QH, Abdelhady HG, and Alsarra I
- Subjects
- Drug Carriers chemistry, Humans, Chitosan chemistry, Glioblastoma drug therapy, Glioblastoma genetics, MicroRNAs genetics, MicroRNAs therapeutic use, Nanoparticles chemistry
- Abstract
Recent evidence has implicated microRNA-219 (miR-219) in regulation of gene contributed in glioblastoma (GBM) pathogenesis. This study aimed to prepare miR-219 in chitosan (CS) nanoparticles (NPs), characterize and investigate their efficacy on human GBM cell line (U87 MG). NPs were prepared using ionic gelation method. The influence of process parameters on physicochemical characteristics of NPs was investigated. Apoptotic effect of miR-219 was examined on U87 MG cells. Formulated NPs showed particle size of 109 ± 2.18 nm, with poly dispersity index equal to 0.2 ± 0.05, and zeta potential of +20.5 ± 0.7 mV. Entrapment efficiency of miR-219 in loaded NP has reached 95%. The in vitro release study demonstrated sustained release pattern of miR-219 from CS-NPs. Gel retardation assay has confirmed the integrity of miR-219 after production process. The fabricated NPs reduced the survival of U87 MG cells to 78% after 24 h of post-transfection, and into 67.5% after 48 h. However, fibroblasts were not affected by the NPs, revealing their specificity for GBM cells. Given the tumour suppressing function of miR-219, and advantage of CS-NPs for gene delivery to the central nervous system, the presented NPs have a great potential for treatment of GBM.
- Published
- 2022
- Full Text
- View/download PDF